Ironwood Pharmaceuticals Makes Progress with Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced positive top-line data from a Phase Ia study of IW-1701, an investigational soluble guanylate cyclase (sGC) stimulator from Ironwood’s vascular and fibrotic disease platform.
According to the company:

In the study, IW-1701 demonstrated the expected cardiovascular pharmacodynamic effects, proof of mechanism for sGC stimulation, a dose range that was well tolerated in healthy volunteers as a single dose, and a pharmacokinetic profile suitable for once-daily dosing and consistent with distribution into tissues.

Mark Currie, Ph.D., chief scientific officer and president of research and development at Ironwood commented:

Today’s positive Phase Ia results with IW-1701 – along with our recent positive Phase Ia data with our other clinical sGC stimulator IW-1973 – demonstrate that Ironwood’s sGC stimulators have attractive pharmacologic and pharmacokinetic profiles, providing multiple opportunities to develop therapies that, if approved, can address important unmet needs.

Click here to view the full press release.